Cardio 365 - introductory page
not logged  
Change language:    

STENT SELECTION FOR PRIMARY ANGIOPLASTY AND OUTCOMES IN THE ERA OF POTENT ANTIPLATELETS. DATA FROM THE MULTICENTER RANDOMIZED PRAGUE-18 TRIAL.

O. Hlinomaz, Z. Moťovska, J. Knot, R. Miklík, M. Hromádka, I. Varvařovský, J. Dušek, J. Jarkovský (Brno, Praha, Plzeň, Pardubice, Hradec Králové)
Topic: Interventional cardiology
Type: Presentation - doctors, CCVRID 2023

Drug-eluting stents (DES) are the recommended stents for primary PCI. This study aimed to de-termine why interventional cardiologists used non-DES and how it influenced patient prognoses. The efficacy and safety outcomes of the different stents were also compared in patients treated with either prasugrel or ticagrelor. Of the PRAGUE-18 study patients, 749 (67.4%) were treated with DES, 296 (26.6%) with bare-metal stents (BMS), and 66 (5.9%) with bioabsorbable vascular scaffold/stents (BVS) between 2013 and 2016. Cardiogenic shock at presentation, left main coro-nary artery disease, especially as the culprit lesion, and right coronary artery stenosis were the reasons for selecting a BMS. The incidence of the primary composite net-clinical endpoint (EP) (death, nonfatal MI, stroke, serious bleeding, or revascularization) at seven days was 2.5% vs. 6.3% and 3.0% in the DES, vs. with BMS and BVS, respectively (HR 2.7; 95% CI 1.419–5.15, p = 0.002 for BMS vs. DES and 1.25 (0.29–5.39) p = 0.76 for BVS vs. DES). Patients with BMS were at higher risk of death at 30 days (HR 2.20; 95% CI 1.01–4.76; for BMS vs. DES, p = 0.045) and at one year (HR 2.1; 95% CI 1.19–3.69; p = 0.01); they also had a higher composite of cardiac death, re-MI, and stroke (HR 1.66; 95% CI 1.0–2.74; p = 0.047) at one year. BMS were associated with a significantly higher rate of primary EP whether treated with prasugrel or ticagrelor. In conclusion, patients with the highest initial risk profile were preferably treated with BMS over BVS. BMS were associated with a significantly higher rate of cardiovascular events whether treated with prasug-rel or ticagrelor.